Compared to Hi receptor antagonists, chemical mediator release blockers (anti-allergic agents) are considered to be more effective in treating nasal obstruction in nasal allergy. However, they also require a longer time before showing a therapeutic effect.
Remicute (emedastine difumarate) has various pharmacological effects such as the inhibition of chemical mediator release from mast cells induced by antigen and substance P and the suppression of eosinophil infiltration in the nasal mucosa.
We evaluated the effects of Remicut (R) 12mg twice daily for 2 weeks on hyperreactive nasal symptoms in 74 subjects with perennial nasal allergy and then compared the number of days required to demonstrate a subjective improvement in sneezing, rhinorrhea and nasal obstruction.
More than a moderate improvement rate for sneezing, rhinorrhea and nasal obstruction was seen in 61.0 %, 65.1%, and 59.0%, respectively, with 74.5% demonstrating a more than moderate final global improvement rate.
The number of days required before a subjective improvement of sneezing, rhinorrhea and nasal obstruction could be seen was 3.6±0.4 days, 4.7±0.7 days and 6.5±0.9 days, respectively, with 5.9±0.7 days for global improvement.
These results thus suggest that Remicut (R) is as effective for nasal obstruction as it is for sneezing and rhinorrhea and the number of days required for a subjective improvement of nasal obstruction is 2-3 days longer than that for sneezing and rhinorrhea.
View full abstract